dalteparin has been researched along with Coronary Disease in 138 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Switching from enoxaparin to bivalirudin for patients with ACS undergoing PCI appears to be clinically safe without increased risk of major bleeding complications, regardless of the time of enoxaparin administration, and is safe enough to warrant testing it in larger numbers." | 9.12 | Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial. ( Kent, KM; Okubagzi, P; Satler, LF; Suddath, WO; Torguson, RL; Waksman, R; Wolfram, RM; Xue, Z, 2006) |
| "A recent randomized, controlled trial, the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS 5) trial, reported that major bleeding was 2-fold less frequent with fondaparinux than with enoxaparin in acute coronary syndromes (ACS)." | 9.12 | Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Fox, KA; Mehta, SR; Moccetti, T; Piegas, LS; Theroux, P; Valentin, V; Wallentin, L; Yusuf, S, 2007) |
| "In this dose-finding study, we sought to compare fondaparinux with enoxaparin in patients with acute coronary syndromes (ACS)." | 9.11 | A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. ( Bobbink, IW; Boland, J; Gardien, M; Klootwijk, P; Lensing, AW; Ruzyllo, W; Simoons, ML; Umans, VA; Vahanian, A; Van De Werf, F; Zeymer, U, 2004) |
| " dalteparin is associated with a low risk of major side effects and is as safe as the combination of abciximab and UFH." | 6.70 | Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. ( Armstrong, P; Califf, R; Husted, S; James, S; Kontny, F; Niemminen, M; Pfisterer, M; Simoons, ML; Wallentin, L, 2002) |
| "Switching from enoxaparin to bivalirudin for patients with ACS undergoing PCI appears to be clinically safe without increased risk of major bleeding complications, regardless of the time of enoxaparin administration, and is safe enough to warrant testing it in larger numbers." | 5.12 | Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial. ( Kent, KM; Okubagzi, P; Satler, LF; Suddath, WO; Torguson, RL; Waksman, R; Wolfram, RM; Xue, Z, 2006) |
| "A recent randomized, controlled trial, the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS 5) trial, reported that major bleeding was 2-fold less frequent with fondaparinux than with enoxaparin in acute coronary syndromes (ACS)." | 5.12 | Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Fox, KA; Mehta, SR; Moccetti, T; Piegas, LS; Theroux, P; Valentin, V; Wallentin, L; Yusuf, S, 2007) |
| "To study efficacy of treating patients with acute coronary syndrome (ACS) without ST segment elevation (STSE) with platelet dysaggregation drugs (aspirin, cardiomagnil, clopidogrel)." | 5.11 | [Dysaggregants effect of platelet aggregation in patients with non-ST segment elevation acute coronary syndrome]. ( Kapilevich, NA; Kisteneva, IV; Markov, VA; Novitskiĭ, VV; Poponina, TM, 2004) |
| "In this dose-finding study, we sought to compare fondaparinux with enoxaparin in patients with acute coronary syndromes (ACS)." | 5.11 | A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. ( Bobbink, IW; Boland, J; Gardien, M; Klootwijk, P; Lensing, AW; Ruzyllo, W; Simoons, ML; Umans, VA; Vahanian, A; Van De Werf, F; Zeymer, U, 2004) |
| "The OASIS-5 trial is a randomized, double-blind trial of fondaparinux versus enoxaparin in 20,000 patients with unstable angina or non-ST-segment elevation myocardial infarction." | 5.11 | Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. ( Bassand, JP; Budaj, A; Chrolavicius, S; Fox, KA; Granger, CB; Joyner, C; Mehta, SR; Peters, RJ; Wallentin, L; Yusuf, S, 2005) |
| "Tirofiban combined with dalteparin was associated with relatively more bleeding complications in the short term, but was effective in reducing the incidence of MACE during long-term clinical follow-up in patients with ACS." | 5.11 | Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome. ( Ahn, YK; Cho, JG; Hong, SN; Hong, YJ; Jeong, MH; Kang, DK; Kang, JC; Kim, JH; Kim, KH; Kim, W; Lee, SH; Lee, YS; Lim, JH; Lim, SY; Moon, Y; Park, HW; Park, JC; Rhew, JY; Yun, KH, 2005) |
| "Our objective was to provide estimates of the frequency of bleeding complications, as defined by means of the Thrombolysis In Myocardial Infarction(TIMI) group, and collect data on clinical efficacy of the combination of tirofiban with enoxaparin plus ASA." | 5.10 | Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and ( Bigonzi, F; Borzak, S; Cohen, M; Frey, MJ; Harris, K; Lis, J; Mukherjee, R; Senatore, F; Théroux, P; Van Mieghem, W; White, HD, 2002) |
| "In patients receiving intracoronary stents, the discontinuation of ticlopidine therapy 14 days after stent placement is associated with a very low frequency of stent thrombosis and other adverse events." | 5.09 | Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. ( Bell, MR; Berger, PB; Grill, DE; Hasdai, D; Holmes, DR; Melby, S, 1999) |
| "During the first 6 days the rate of death and new myocardial infarction was lower in the dalteparin group than in the placebo group (13 [1." | 5.08 | Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. ( , 1996) |
| "Antithrombotic and antiplatelet agents, particularly unfractionated heparin and aspirin, are longstanding therapeutic mainstays for acute coronary syndromes such as unstable angina and non-Q-wave myocardial infarction (MI)." | 4.80 | Anticoagulants in acute coronary syndromes. ( Turpie, AG, 1999) |
| " Enoxaparin does not activate platelets, has a more predictable dose response that facilitates weight-adjusted dosing and may have enhanced antithrombotic (increased anti-Xa activity) and safety (reduced anti-IIa activity) properties when compared with unfractionated heparin." | 3.79 | Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first". ( Barr, L; Broderick, T; Brodie, B; Casale, P; Christy, G; Cohen, M; Fry, E; Kereiakes, DJ; Lengerich, R; Matthai, W; Moliterno, D; Niederman, A; Shimshak, T; Zidar, J, 2000) |
| "Minor bleeding was more frequent in the enoxaparin group (30." | 2.71 | Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. ( Armstrong, PW; Fitchett, D; Goodman, SG; Langer, A; Tan, M, 2003) |
| " According to our model no dosage adjustment from the standard 1." | 2.71 | Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. ( Atherton, J; Green, B; Greenwood, M; Kluver, L; Rowell, J; Saltissi, D; Westhuyzen, J, 2005) |
| " dalteparin is associated with a low risk of major side effects and is as safe as the combination of abciximab and UFH." | 2.70 | Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. ( Armstrong, P; Califf, R; Husted, S; James, S; Kontny, F; Niemminen, M; Pfisterer, M; Simoons, ML; Wallentin, L, 2002) |
| " UFH is limited due to its unpredictable antithrombotic effect, poor bioavailability when given subcutaneously, requirement for hospitalization and need for frequent laboratory monitoring." | 2.69 | Management of acute coronary syndromes with low molecular weight heparin: TIMI 11A and 11B. ( Turpie, AG, 1998) |
| " This study was designed to test the hypothesis that 3 months of subcutaneous dosing of ardeparin would reduce angiographic restenosis after coronary balloon angioplasty." | 2.69 | Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal coronary angioplasty. ( Gimple, LW; Herrmann, HC; Mammen, E; Winniford, M, 1999) |
| "Angiographic restenosis was defined as a loss of 50% of the initial gain as measured by quantitative coronary angiography (QCA) at a core laboratory." | 2.67 | Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial. ( Califf, R; Coté, G; Dorosti, K; Douglas, J; Faxon, DP; Gordon, JB; Gottlieb, R; Minor, S; Spiro, TE; Topol, E, 1994) |
| " Various clinical studies in unstable angina and acute coronary syndrome have proved that clivarine in a dosage of 3436anti-Xa units twice daily is an effective antithrombotic agent." | 2.42 | Reviparin sodium clivarine: a review of its therapeutic use. ( Gore, M; Kelkar, P; Rege, N; Ross, C, 2004) |
| "Dalteparin has been subjected to a large number of well designed randomised clinical trials for the prevention and treatment of venous thromboembolism." | 2.42 | Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases. ( Hull, RD; Pineo, GF, 2004) |
| " Compared with unfractionated heparin (UFH), the drug has markedly improved bioavailability and increased plasma elimination half-life, and exerts a greater inhibitory effect on plasma activity of coagulation factor Xa relative to its effects on other coagulation parameters." | 2.41 | Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease. ( Dunn, CJ; Jarvis, B, 2000) |
| "Of these, macroscopic thrombus was observed on PCI equipment in 6 patients (5%) necessitating withdrawal of all catheters and wires." | 1.34 | Macroscopic thrombus formation on angioplasty equipment following antithrombin therapy with enoxaparin. ( Barbeau, GR; Cloutier, S; Dana, A; Nguyen, CM, 2007) |
| " The extent to which bleeding risk is attributable to excess dosing of enoxaparin is unclear." | 1.34 | Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes. ( Alexander, KP; Chen, AY; Gibler, BW; LaPointe, NM; Lytle, BL; Ohman, ME; Peterson, ED; Pollack, CV; Roe, MT, 2007) |
| "Fondaparinux is a synthetic penta-saccharide which may be regarded as an extreme low-molecular-weight heparin with a ratio of anti-factor Xa : anti-factor IIa activity as 1 : 0, and with a promising efficacy/safety profile." | 1.33 | [Is there a difference between low-molecular-weight heparins?]. ( Eritsland, J, 2005) |
| " Dosing was determined individually by the investigators with a goal of maintaining an AT activity of 80 to 150 percent." | 1.32 | Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. ( Bauer, KA; Bonfiglio, J; Greist, A; Holmes, HE; Konkle, BA; Weinstein, R, 2003) |
| "To describe dosing practices and to identify risk factors for bleeding in patients with an acute coronary syndrome (ACS) who received treatment with enoxaparin." | 1.32 | Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. ( Douketis, JD; Forbes, L; Foster, GA; Macie, C, 2004) |
| "Although the relationship between anti-Xa activity, efficacy, and adverse effects has not been definitively established, anti-Xa levels can assist with dosing of enoxaparin in renally impaired patients." | 1.32 | Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease. ( Jackevicius, CA; Ma, JM; Yeo, E, 2004) |
| "Outpatient treatment of acute proximal deep vein thrombosis with enoxaparin has also been shown to be cost effective compared with inpatient treatment using UFH." | 1.31 | Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes. ( Bergqvist, D, 2002) |
| "Dalteparin in combination with abciximab in patients with unstable angina undergoing coronary intervention appears to be safe." | 1.31 | Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab. ( Barnard, MR; Broderick, TM; Fox, ML; Frelinger, AL; Furman, MI; Howard, WL; Kereiakes, DJ; Krueger, LA; Michelson, AD; Mueller, MN; Pieper, K; Schneider, JF, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 32 (23.19) | 18.2507 |
| 2000's | 106 (76.81) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Poponina, TM | 1 |
| Kapilevich, NA | 1 |
| Kisteneva, IV | 1 |
| Markov, VA | 1 |
| Novitskiĭ, VV | 1 |
| Lablanche, JM | 2 |
| McFadden, EP | 1 |
| Meneveau, N | 2 |
| Lusson, JR | 1 |
| Bertrand, B | 1 |
| Metzger, JP | 1 |
| Legrand, V | 1 |
| Grollier, G | 2 |
| Macaya, C | 1 |
| de Bruyne, B | 1 |
| Vahanian, A | 2 |
| Grentzinger, A | 1 |
| Masquet, C | 1 |
| Wolf, JE | 2 |
| Tobelem, G | 1 |
| Fontecave, S | 1 |
| Vacheron, A | 1 |
| d'Azemar, P | 1 |
| Bertrand, ME | 1 |
| Zed, PJ | 3 |
| Tisdale, JE | 1 |
| Borzak, S | 2 |
| Widimský, P | 1 |
| Schiele, F | 1 |
| Farah, B | 1 |
| Khalifé, K | 1 |
| Machecourt, J | 1 |
| Danchin, N | 1 |
| Simpson, M | 1 |
| Hak, JB | 1 |
| Bassand, JP | 3 |
| Antman, EM | 5 |
| Goldmann, BU | 1 |
| Hamm, CW | 1 |
| Ottani, F | 1 |
| Ferrini, D | 1 |
| Di Pasquale, G | 1 |
| Galvani, M | 1 |
| Al-Sallami, H | 1 |
| Ferguson, R | 1 |
| Wilkins, G | 1 |
| Gray, A | 1 |
| Medlicott, NJ | 1 |
| Cohen, M | 15 |
| Théroux, P | 3 |
| Frey, MJ | 1 |
| White, HD | 3 |
| Van Mieghem, W | 1 |
| Senatore, F | 1 |
| Lis, J | 1 |
| Mukherjee, R | 1 |
| Harris, K | 1 |
| Bigonzi, F | 1 |
| Cannon, CP | 1 |
| Borja, J | 3 |
| Jones, HU | 1 |
| Muhlestein, JB | 1 |
| Jones, KW | 1 |
| Bair, TL | 1 |
| Lavasani, F | 1 |
| Sohrevardi, M | 1 |
| Horne, BD | 1 |
| Doty, D | 1 |
| Lappe, DL | 1 |
| Brosa, M | 1 |
| Rubio-Terrés, C | 1 |
| Farr, I | 1 |
| Nadipelli, V | 1 |
| Froufe, J | 1 |
| Fitchett, D | 2 |
| Goodman, SG | 3 |
| Gupta, M | 1 |
| Langer, A | 2 |
| Armstrong, PW | 2 |
| Tan, M | 1 |
| Konkle, BA | 1 |
| Bauer, KA | 1 |
| Weinstein, R | 1 |
| Greist, A | 1 |
| Holmes, HE | 1 |
| Bonfiglio, J | 1 |
| Orlewska, E | 1 |
| Budaj, A | 2 |
| Tereszkowski-Kaminski, D | 1 |
| Kincaid, EH | 1 |
| Monroe, ML | 1 |
| Saliba, DL | 1 |
| Kon, ND | 1 |
| Byerly, WG | 1 |
| Reichert, MG | 1 |
| Spinler, SA | 2 |
| Inverso, SM | 1 |
| Stringer, KA | 1 |
| Streif, W | 1 |
| Goebel, G | 1 |
| Chan, AK | 1 |
| Massicotte, MP | 1 |
| Gratsianskiĭ, NA | 2 |
| Levine, GN | 2 |
| Ferguson, JJ | 7 |
| Cheong, B | 1 |
| O'Meallie, L | 1 |
| Diez, JG | 1 |
| Bates, ER | 1 |
| Every, NR | 1 |
| Harrington, RA | 2 |
| Pepine, CJ | 1 |
| Averkov, OV | 1 |
| Slavina, NN | 1 |
| Dobrovol'skiĭ, AB | 1 |
| Bosanquet, N | 1 |
| Jönsson, B | 1 |
| Fox, KA | 5 |
| Grines, CL | 3 |
| O'Neill, W | 1 |
| Aydin, M | 1 |
| Ozeren, A | 1 |
| Bilge, M | 1 |
| Gursurer, M | 1 |
| Ozdemir, H | 1 |
| Savranlar, A | 1 |
| Bijsterveld, NR | 1 |
| Peters, RJ | 2 |
| Murphy, SA | 1 |
| Bernink, PJ | 1 |
| Tijssen, JG | 1 |
| Lee, DS | 1 |
| Bhatt, DL | 1 |
| Moliterno, DJ | 2 |
| Peacock, WF | 1 |
| Ellis, SG | 1 |
| Topol, EJ | 2 |
| Hermiller, JB | 1 |
| Macie, C | 1 |
| Forbes, L | 1 |
| Foster, GA | 1 |
| Douketis, JD | 1 |
| Simoons, ML | 2 |
| Bobbink, IW | 1 |
| Boland, J | 1 |
| Gardien, M | 1 |
| Klootwijk, P | 1 |
| Lensing, AW | 1 |
| Ruzyllo, W | 1 |
| Umans, VA | 1 |
| Van De Werf, F | 1 |
| Zeymer, U | 2 |
| Genest, M | 1 |
| Pochmalicki, G | 1 |
| Ma, JM | 1 |
| Jackevicius, CA | 1 |
| Yeo, E | 1 |
| Ferrando, T | 1 |
| Steg, PG | 1 |
| Juliard, JM | 1 |
| de Lemos, JA | 1 |
| Blazing, MA | 1 |
| Wiviott, SD | 1 |
| Brady, WE | 1 |
| Palmisano, J | 1 |
| Ramsey, KE | 1 |
| Bilheimer, DW | 1 |
| Lewis, EF | 1 |
| Pfeffer, M | 1 |
| Califf, RM | 4 |
| Braunwald, E | 1 |
| Green, B | 1 |
| Greenwood, M | 1 |
| Saltissi, D | 1 |
| Westhuyzen, J | 1 |
| Kluver, L | 1 |
| Rowell, J | 1 |
| Atherton, J | 1 |
| Galla, JM | 1 |
| Mahaffey, KW | 4 |
| Rokos, IC | 1 |
| Das, P | 1 |
| Becker, RC | 1 |
| Petersen, JL | 2 |
| Hasselblad, V | 2 |
| Eritsland, J | 1 |
| Mehta, SR | 2 |
| Yusuf, S | 3 |
| Granger, CB | 1 |
| Wallentin, L | 13 |
| Joyner, C | 1 |
| Chrolavicius, S | 2 |
| Zalc, S | 1 |
| Lemos, PA | 2 |
| Esteves, A | 1 |
| Ribeiro, EE | 1 |
| Horta, P | 1 |
| Nicolau, JC | 1 |
| Ramires, JA | 1 |
| Martinez, EE | 1 |
| Chen, JL | 2 |
| Chen, J | 2 |
| Qiao, SB | 2 |
| Guo, YL | 1 |
| Wu, YJ | 2 |
| Dai, J | 2 |
| Yuan, JQ | 2 |
| Qin, XW | 2 |
| Yang, YJ | 2 |
| Gao, RL | 2 |
| Yao, M | 1 |
| Gitt, A | 1 |
| Jünger, C | 1 |
| Koeth, O | 1 |
| Zahn, R | 1 |
| Wienbergen, H | 1 |
| Gottwik, M | 1 |
| Senges, J | 1 |
| Waksman, R | 1 |
| Wolfram, RM | 1 |
| Torguson, RL | 1 |
| Okubagzi, P | 1 |
| Xue, Z | 1 |
| Suddath, WO | 1 |
| Satler, LF | 1 |
| Kent, KM | 1 |
| Kleiman, NS | 1 |
| Lokhnygina, Y | 1 |
| Pieper, KS | 1 |
| Chiswell, K | 1 |
| Chew, DP | 1 |
| Berdan, LG | 1 |
| Aylward, PE | 1 |
| Nessel, CC | 1 |
| Ugo, F | 1 |
| Ardissino, D | 1 |
| Renda, G | 1 |
| Di Pillo, R | 1 |
| D'Alleva, A | 1 |
| Sciartilli, A | 1 |
| Zimarino, M | 1 |
| De Candia, E | 1 |
| Landolfi, R | 1 |
| Di Giammarco, G | 1 |
| Calafiore, A | 1 |
| De Caterina, R | 1 |
| Helft, G | 1 |
| Dana, A | 1 |
| Nguyen, CM | 1 |
| Cloutier, S | 1 |
| Barbeau, GR | 1 |
| LaPointe, NM | 1 |
| Chen, AY | 1 |
| Alexander, KP | 1 |
| Roe, MT | 1 |
| Pollack, CV | 1 |
| Lytle, BL | 1 |
| Ohman, ME | 1 |
| Gibler, BW | 1 |
| Peterson, ED | 1 |
| Piegas, LS | 1 |
| Valentin, V | 1 |
| Moccetti, T | 1 |
| Afzal, R | 1 |
| Little, M | 1 |
| Johnstone, C | 1 |
| Famularo, G | 1 |
| Minisola, G | 1 |
| Faxon, DP | 1 |
| Spiro, TE | 1 |
| Minor, S | 1 |
| Coté, G | 1 |
| Douglas, J | 1 |
| Gottlieb, R | 1 |
| Califf, R | 2 |
| Dorosti, K | 1 |
| Topol, E | 1 |
| Gordon, JB | 1 |
| Grozovski, ES | 1 |
| Cohen, JD | 1 |
| Grunberg, G | 1 |
| Keslin, J | 1 |
| Gassner, S | 1 |
| Ganjoo, AK | 1 |
| Harloff, MG | 1 |
| Johnson, WD | 1 |
| Piazza, V | 1 |
| Rulli, F | 1 |
| Mark, DB | 1 |
| Cowper, PA | 1 |
| Berkowitz, SD | 1 |
| Davidson-Ray, L | 1 |
| DeLong, ER | 1 |
| Turpie, AG | 3 |
| Weatherley, B | 1 |
| Noble, S | 1 |
| Spencer, CM | 1 |
| Mark, D | 1 |
| Zidar, JP | 2 |
| Berger, PB | 2 |
| Bell, MR | 1 |
| Hasdai, D | 1 |
| Grill, DE | 1 |
| Melby, S | 1 |
| Holmes, DR | 1 |
| Stone, GW | 1 |
| Gurfinkel, E | 1 |
| Duronto, E | 1 |
| Colorio, C | 1 |
| Bozovich, G | 1 |
| Mautner, B | 1 |
| Stein, K | 1 |
| Nicholson, T | 1 |
| Check, W | 1 |
| Rabah, MM | 1 |
| Premmereur, J | 1 |
| Graham, M | 1 |
| Fareed, J | 3 |
| Hoppensteadt, DA | 1 |
| Grines, LL | 1 |
| Brener, SJ | 1 |
| Balen, RM | 1 |
| Marra, CA | 1 |
| Frighetto, L | 1 |
| O'Brien, BJ | 1 |
| Willan, A | 1 |
| Blackhouse, G | 1 |
| Goeree, R | 1 |
| Goodman, S | 1 |
| Kereiakes, DJ | 4 |
| Fry, E | 2 |
| Matthai, W | 2 |
| Niederman, A | 1 |
| Barr, L | 2 |
| Brodie, B | 2 |
| Zidar, J | 2 |
| Casale, P | 1 |
| Christy, G | 1 |
| Moliterno, D | 1 |
| Lengerich, R | 1 |
| Broderick, T | 2 |
| Shimshak, T | 1 |
| Galli, M | 1 |
| Toomey, JR | 1 |
| Blackburn, MN | 1 |
| Storer, BL | 1 |
| Valocik, RE | 1 |
| Koster, PF | 1 |
| Feuerstein, GZ | 1 |
| Nahlawi, M | 1 |
| Benzuly, K | 1 |
| Fintel, D | 1 |
| Young, JJ | 1 |
| Grines, C | 1 |
| Esente, P | 1 |
| Hoppensteadt, D | 1 |
| Midei, M | 1 |
| Todd, M | 1 |
| Rubinstein, R | 1 |
| Santoian, E | 1 |
| Neiderman, A | 1 |
| Vila, V | 1 |
| Martínez-Sales, V | 1 |
| Réganon, E | 1 |
| Peris, E | 1 |
| Perez, F | 1 |
| Ruano, M | 1 |
| Aznar, J | 1 |
| Batchelor, WB | 1 |
| Deutsch, E | 1 |
| Meier, S | 1 |
| Fry, ET | 1 |
| Teirstein, PS | 1 |
| Ross, AM | 1 |
| Binanay, CA | 1 |
| Olivella, P | 2 |
| Bergqvist, D | 1 |
| Toquero Ramos, J | 1 |
| Silva Melchor, L | 1 |
| Jiménez Mazuecos, J | 1 |
| Ortigosa Aso, J | 1 |
| Brieger, D | 1 |
| Solanki, V | 1 |
| Gaynor, M | 1 |
| Booth, V | 1 |
| MacDonald, R | 1 |
| Freedman, SB | 1 |
| Ibbotson, T | 1 |
| Goa, KL | 1 |
| Gore, M | 1 |
| Kelkar, P | 1 |
| Rege, N | 1 |
| Ross, C | 1 |
| Preisack, MB | 3 |
| Karsch, KR | 4 |
| Baildon, R | 2 |
| Eschenfelder, V | 2 |
| Foley, D | 2 |
| Garcia, EJ | 1 |
| Kaltenbach, M | 2 |
| Meisner, C | 3 |
| Selbmann, HK | 2 |
| Serruys, PW | 2 |
| Shiu, MF | 2 |
| Sujatta, M | 2 |
| Bonan, R | 2 |
| Garcia, E | 1 |
| Baumbach, A | 1 |
| Oberhoff, M | 1 |
| Herdeg, C | 1 |
| Lerch, M | 1 |
| Schröder, S | 1 |
| Rübsamen, K | 1 |
| James, S | 1 |
| Armstrong, P | 1 |
| Husted, S | 3 |
| Kontny, F | 3 |
| Niemminen, M | 1 |
| Pfisterer, M | 1 |
| Marmur, JD | 1 |
| Anand, SX | 1 |
| Bagga, RS | 1 |
| Pan, CM | 1 |
| Sharma, SK | 1 |
| Richard, MF | 1 |
| Casserly, IP | 1 |
| Tarasov, NI | 1 |
| Terent'eva, NV | 1 |
| Vorontsova, NL | 1 |
| Barbarash, LS | 1 |
| Pineo, GF | 1 |
| Hull, RD | 1 |
| Kim, JH | 1 |
| Jeong, MH | 1 |
| Rhew, JY | 1 |
| Lim, JH | 1 |
| Yun, KH | 1 |
| Kim, KH | 1 |
| Kang, DK | 1 |
| Hong, SN | 1 |
| Lim, SY | 1 |
| Lee, SH | 1 |
| Lee, YS | 1 |
| Hong, YJ | 1 |
| Park, HW | 1 |
| Kim, W | 1 |
| Ahn, YK | 1 |
| Moon, Y | 1 |
| Cho, JG | 1 |
| Park, JC | 1 |
| Kang, JC | 1 |
| Komarov, AL | 1 |
| Panchenko, EP | 1 |
| James, SK | 1 |
| Oldgren, J | 1 |
| Lindbäck, J | 1 |
| Johnston, N | 1 |
| Siegbahn, A | 4 |
| Ripa, RS | 1 |
| Holmvang, L | 1 |
| Maynard, C | 1 |
| Sejersten, M | 1 |
| Clemmensen, P | 1 |
| Grande, P | 1 |
| Lindahl, B | 5 |
| Lagerqvist, B | 3 |
| Wagner, GS | 1 |
| Mälarstig, A | 2 |
| Mikhailidis, DP | 1 |
| Jagroop, IA | 1 |
| Ganotakis, E | 1 |
| Knight, CJ | 1 |
| Goodall, AH | 1 |
| Venge, P | 2 |
| Swahn, E | 3 |
| Pan, M | 1 |
| Suárez de Lezo, J | 1 |
| Medina, A | 1 |
| Romero, M | 1 |
| Hernández, E | 1 |
| Segura, J | 1 |
| Melian, F | 1 |
| Wangüemert, F | 1 |
| Landin, M | 1 |
| Benítez, F | 1 |
| Amat, M | 1 |
| Velasco, F | 1 |
| Torres, A | 1 |
| Toss, H | 1 |
| Säfström, K | 1 |
| Eikelboom, JW | 1 |
| Massel, D | 1 |
| Cohen, AT | 1 |
| Ståhle, E | 1 |
| Dunn, CJ | 1 |
| Jarvis, B | 1 |
| Verheugt, FW | 1 |
| Chesebro, JH | 1 |
| Furman, MI | 1 |
| Krueger, LA | 1 |
| Mueller, MN | 1 |
| Pieper, K | 1 |
| Broderick, TM | 1 |
| Schneider, JF | 1 |
| Howard, WL | 1 |
| Fox, ML | 1 |
| Barnard, MR | 1 |
| Frelinger, AL | 1 |
| Michelson, AD | 1 |
| Diderholm, E | 1 |
| Andrén, B | 1 |
| Frostfeldt, G | 1 |
| Genberg, M | 1 |
| Jernberg, T | 2 |
| Abrahamsson, P | 1 |
| Johanson, P | 1 |
| Dellborg, M | 1 |
| Gimple, LW | 1 |
| Herrmann, HC | 1 |
| Winniford, M | 1 |
| Mammen, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Low Molecular Weight Heparin vs Unfractionated Heparin on Bleeding After Cardiac Surgery[NCT00420667] | 43 participants (Actual) | Interventional | 2004-11-30 | Completed | |||
| Pharmacokinetics of Recombinant Antithrombin III in Neonates Undergoing Extracorporeal Membrane Oxygenation[NCT01913444] | Phase 4 | 0 participants (Actual) | Interventional | 2013-07-31 | Withdrawn (stopped due to Unable to enroll patients into study.) | ||
| A Multicenter, Randomized, Controlled, Double-Blind Trial to Investigate the Clinical Efficacy and Tolerability of Early Treatment With Simvastatin 40 mg Daily for 30 Days, Followed by Simvastatin 80 mg Daily Thereafter in Tirofiban-Treated Acute Coronary[NCT00251576] | Phase 3 | 4,497 participants (Actual) | Interventional | 1999-11-01 | Completed | ||
| An International Randomised Trial of Early Versus Delayed Invasive Strategies in Patients With Non-ST Segment Elevation Acute Coronary Syndromes[NCT00552513] | 3,031 participants (Actual) | Interventional | 2005-05-31 | Completed | |||
| Approaches to Chronic Occlusions With Sirolimus Stents-Cypher (ACROSS-Cypher) Total Occlusion Study of Coronary Arteries 4 Trial[NCT00378612] | Phase 3 | 200 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention[NCT03145675] | Phase 4 | 378 participants (Actual) | Interventional | 2017-05-12 | Completed | ||
| A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796] | Phase 3 | 1,473 participants (Actual) | Interventional | 2006-12-31 | Active, not recruiting | ||
| A Clinical Trial of Conservative Versus Routine Invasive Management in Patients With Prior Coronary Artery Bypass Surgery in Patients With a Non-ST Elevation Acute Coronary Syndrome: a Pilot Trial and Registry.[NCT01895751] | Phase 4 | 60 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angiography in Elderly Patients With Ischemia: a Multicentric Randomized Non Inferiority Trial.[NCT03289728] | 1,756 participants (Anticipated) | Interventional | 2018-04-04 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00552513)
Timeframe: 180 days
| Intervention | Eparticipants (Number) |
|---|---|
| Early Intervention | 264 |
| Delayed Intervention | 280 |
(NCT00552513)
Timeframe: 180 days
| Intervention | participants (Number) |
|---|---|
| Early Intervention | 153 |
| Delayed Intervention | 163 |
(NCT00552513)
Timeframe: 180 days
| Intervention | participants (Number) |
|---|---|
| Early Intervention | 151 |
| Delayed Intervention | 186 |
24 reviews available for dalteparin and Coronary Disease
| Article | Year |
|---|---|
Low-molecular-weight heparins in the management of acute coronary syndromes.
Topics: Angina, Unstable; Canada; Coronary Disease; Dalteparin; Enoxaparin; Fibrinolytic Agents; Hemorrhage; | 1999 |
The search for replacements for unfractionated heparin.
Topics: Acute Disease; Antithrombins; Clinical Trials as Topic; Coronary Disease; Dalteparin; Enoxaparin; Fi | 2001 |
[Low-molecular weight heparin and acute coronary syndrome: theoretical background and its use in clinical practice].
Topics: Acute Disease; Anticoagulants; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Daltepar | 2001 |
Defining optimal therapy for the thrombolysis-ineligible patient.
Topics: Acute Disease; Coronary Disease; Enoxaparin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Wei | 2002 |
Preventing thrombosis: update of first-line therapy in the management of non-ST segment elevation acute coronary syndromes.
Topics: Acute Disease; Algorithms; Clopidogrel; Coronary Disease; Coronary Thrombosis; Enoxaparin; Fibrinoly | 2002 |
Low-molecular-weight heparin during percutaneous coronary interventions: rationale, results, and recommendations.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Coronary Disease; Enoxapari | 2003 |
Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Coronary | 2003 |
The role of enoxaparin in interventional management of patients with acute coronary syndromes.
Topics: Acute Disease; Anticoagulants; Blood Coagulation Factors; Cardiac Catheterization; Combined Modality | 2003 |
[Acute coronary syndromes without ST segment elevation].
Topics: Acute Disease; Adrenergic beta-Antagonists; Analgesics, Opioid; Angina Pectoris; Angiotensin-Convert | 2004 |
Clinical use of enoxaparin in the management of non-ST segment elevation acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Coronary Disease; Enoxaparin; Heparin; Humans; Myoc | 2005 |
Enoxaparin in clinical practice and clinical trials of non-ST-elevation Acute Coronary Syndrome (NSTE-ACS).
Topics: Acute Disease; Clinical Protocols; Coronary Disease; Electrocardiography; Enoxaparin; Heparin; Human | 2005 |
[Low-molecular-weight heparins in acute coronary syndrome: acquired results and new perspectives].
Topics: Acute Disease; Algorithms; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Electrocardi | 2006 |
Enoxaparin. A review of its clinical potential in the management of coronary artery disease.
Topics: Angina, Unstable; Angioplasty; Coronary Disease; Drug Tolerance; Enoxaparin; Fibrinolytic Agents; Hu | 1998 |
Anticoagulants in acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease | 1999 |
Clinical trials of low-molecular-weight heparins in cardiology.
Topics: Acute Disease; Biomarkers; Clinical Trials as Topic; Coronary Disease; Enoxaparin; Fibrinolytic Agen | 1999 |
Unfractionated and low-molecular-weight heparins in acute coronary syndromes: current recommendations.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Enoxaparin; F | 2000 |
Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first".
Topics: Abciximab; Acute Disease; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Co | 2000 |
Low molecular weight heparins and coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Coronary Disease; Enoxaparin; Heparin, Low-Molecular-Weight; Human | 2000 |
Antithrombotic therapy in acute coronary syndromes: key notes from ESSENCE and TIMI 11B.
Topics: Acute Disease; Anticoagulants; Clinical Trials as Topic; Coronary Disease; Enoxaparin; Fibrinolytic | 2001 |
Enoxaparin: an update of its clinical use in the management of acute coronary syndromes.
Topics: Acute Disease; Animals; Anticoagulants; Coronary Disease; Enoxaparin; Humans | 2002 |
Reviparin sodium clivarine: a review of its therapeutic use.
Topics: Anticoagulants; Coronary Disease; Coronary Restenosis; Heparin, Low-Molecular-Weight; Humans; Myocar | 2004 |
Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases.
Topics: Anticoagulants; Blood Coagulation; Coronary Disease; Dalteparin; Heparin, Low-Molecular-Weight; Huma | 2004 |
[Low-molecular heparins in the treatment of non-ST elevation acute coronary syndrome].
Topics: Acute Disease; Coronary Disease; Dalteparin; Humans | 2004 |
Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.
Topics: Blood Coagulation; Coronary Disease; Dalteparin; Drug Costs; Drug Interactions; Economics, Pharmaceu | 2000 |
58 trials available for dalteparin and Coronary Disease
| Article | Year |
|---|---|
[Dysaggregants effect of platelet aggregation in patients with non-ST segment elevation acute coronary syndrome].
Topics: Acute Disease; Aspirin; Blood Platelets; Clopidogrel; Coronary Disease; Electrocardiography; Female; | 2004 |
Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronaire Transluminale.
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Coron | 1997 |
Local delivery of nadroparin for the prevention of neointimal hyperplasia following stent implantation: results of the IMPRESS trial. A multicentre, randomized, clinical, angiographic and intravascular ultrasound study.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Female; Follow- | 2000 |
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combin | 2002 |
Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide.
Topics: Acute Disease; Aged; Aspirin; Coronary Disease; Electrocardiography; Enoxaparin; Eptifibatide; Femal | 2003 |
Effects of preoperative enoxaparin versus unfractionated heparin on bleeding indices in patients undergoing coronary artery bypass grafting.
Topics: Aged; Blood Transfusion; Coronary Artery Bypass; Coronary Disease; Dose-Response Relationship, Drug; | 2003 |
[Enoxaparin failed to show superiority to unfractionated heparin in patients with non ST-elevation acute coronary syndrome in a phase of A to Z trial].
Topics: Acute Disease; Anticoagulants; Coronary Disease; Enoxaparin; Heparin; Humans; Syndrome; Treatment Fa | 2003 |
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; | 2003 |
Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: results from the Thrombolysis in Myocardial Infarction (TIMI) 11B and Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave C
Topics: Anticoagulants; Coronary Disease; Drug Therapy, Combination; Enoxaparin; Heparin, Low-Molecular-Weig | 2003 |
The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Disease; Drug Therapy, Combi | 2004 |
A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Angioplasty, Balloon, Coronary; Angiotensin-Conve | 2004 |
Degree of anticoagulation after one subcutaneous and one subsequent intravenous booster dose of enoxaparin: implications for patients with acute coronary syndromes undergoing early percutaneous coronary intervention.
Topics: Acute Disease; Adult; Aged; Angioplasty, Balloon, Coronary; Antithrombin III; Blood Coagulation Test | 2004 |
Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial.
Topics: Aspirin; Coronary Disease; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Hepar | 2004 |
Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Anticoagulants; Coronary Disease; Enoxapa | 2005 |
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Coronary Disease; Double-Blind Method; Enoxap | 2005 |
Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin.
Topics: Aged; Anticoagulants; Coronary Disease; Device Removal; Early Ambulation; Enoxaparin; Factor Xa; Fac | 2006 |
A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Disease; Enoxaparin; Factor Xa Inhibitors; | 2006 |
[A randomized comparative study of using enoxaparin or UFH adjunctive to percutaneous coronary intervention in patients with CHD (ROUTE)].
Topics: Angioplasty, Balloon, Coronary; Coronary Disease; Enoxaparin; Female; Heparin; Humans; Male; Middle | 2006 |
Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Disease; Enoxaparin; F | 2006 |
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revas
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Blood Transfusion; Coronary Dis | 2006 |
Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation Tests; Blood Loss, Surgical; Coronary Artery Bypass; | 2007 |
Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Anticoagulants; Coronary Disease; Death, Sudden, Cardiac; | 2007 |
Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial.
Topics: Angioplasty, Balloon, Coronary; Constriction, Pathologic; Coronary Angiography; Coronary Disease; Do | 1994 |
Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [un
Topics: Acute Disease; Anticoagulants; Coronary Disease; Double-Blind Method; Enoxaparin; Female; Health Car | 1998 |
Management of acute coronary syndromes with low molecular weight heparin: TIMI 11A and 11B.
Topics: Acute Disease; Angina, Unstable; Coronary Disease; Enoxaparin; Female; Fibrinolytic Agents; Heparin, | 1998 |
When innovative therapies make economic sense: economic analysis of enoxaparin versus unfractionated heparin in the ESSENCE trial--an overview. Efficacy and Safety of Subcutaneous in non-Q Wave Coronary Events.
Topics: Coronary Disease; Drug Costs; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Male; Unite | 1998 |
Low molecular weight heparin in coronary stenting.
Topics: Coronary Disease; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Pilot Proj | 1998 |
Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Coronary Disease; Drug Administra | 1999 |
Thrombotic reactant markers in non-ST segment elevation acute coronary syndromes treated with either enoxaparin (low molecular weight heparin) or unfractionated heparin.
Topics: Biomarkers; Coronary Disease; Double-Blind Method; Electrocardiography; Enoxaparin; Female; Fibrinol | 1999 |
Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Enoxa | 1999 |
Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes. A Canadian hospital perspective.
Topics: Acute Disease; Anticoagulants; Canada; Coronary Disease; Cost-Benefit Analysis; Decision Support Tec | 1999 |
Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Canada; Cardiac Cath | 2000 |
Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first".
Topics: Abciximab; Acute Disease; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Co | 2000 |
Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: the NICE 3 story. National Investigators Collaborating on Enoxaparin.
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Therapy, Co | 2000 |
Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; | 2000 |
Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; | 2001 |
Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes.
Topics: Acute Disease; Aged; Aged, 80 and over; Coronary Disease; Enoxaparin; Female; Hemostatics; Heparin; | 2001 |
A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial.
Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Coronary Disease; Coronary Thrombosis; Double-B | 2001 |
The SYNERGY trial: study design and rationale.
Topics: Acute Disease; Adult; Aged; Angina, Unstable; Anticoagulants; Coronary Disease; Enoxaparin; Fibrinol | 2002 |
Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early A
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Coronary Disease; Coronary Ves | 1996 |
[Low molecular weight heparin, reviparin, after PTCA: results of a randomized double-blind, standard heparin and placebo controlled multicenter study (REDUCE Study].
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Cell Division; Coronary Angiography; Coronary Disease; | 1997 |
Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes.
Topics: Abciximab; Acute Disease; Aged; Antibodies, Monoclonal; Anticoagulants; Cohort Studies; Coronary Dis | 2002 |
[Dynamics of lipid peroxidation and antioxidant defense in response to dalteparin therapy in acute coronary syndrome].
Topics: Acute Disease; Antioxidants; Coronary Disease; Dalteparin; Female; Fibrinolytic Agents; Humans; Lipi | 2004 |
Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome.
Topics: Acute Disease; Aged; Coronary Disease; Dalteparin; Drug Therapy, Combination; Female; Hemorrhage; He | 2005 |
Consideration of the total ST-segment deviation on the initial electrocardiogram for predicting final acute posterior myocardial infarct size in patients with maximum ST-segment deviation as depression in leads V1 through V3. A FRISC II substudy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Dalteparin; Electrocardiography; Female; | 2005 |
Soluble CD40L levels are regulated by the -3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Base Sequence; Biomarkers; CD40 Ligand; Coronary Dise | 2006 |
Genetic variation in the interleukin-6 gene in relation to risk and outcomes in acute coronary syndrome.
Topics: Acute Disease; Anticoagulants; C-Reactive Protein; Case-Control Studies; Coronary Disease; Daltepari | 2007 |
Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Coronary Disease; Daltepa | 1996 |
Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group.
Topics: Aged; Biomarkers; Coronary Disease; Dalteparin; Double-Blind Method; Drug Administration Schedule; F | 1997 |
Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study).
Topics: Angina, Unstable; Anticoagulants; Coronary Angiography; Coronary Disease; Dalteparin; Drug Therapy, | 1997 |
In-laboratory removal of femoral sheath following protamine administration in patients having intracoronary stent implantation.
Topics: Anticoagulants; Coronary Disease; Dalteparin; Female; Femoral Artery; Hemorrhage; Heparin; Heparin A | 1997 |
Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease.
Topics: Adult; Angina, Unstable; Anticoagulants; Blood Coagulation; Coronary Disease; Dalteparin; Drug Admin | 1999 |
Early symptom-limited exercise test for risk stratification in post menopausal women with unstable coronary artery disease. FRISC study group. Fragmin during Instability in Coronary Artery Disease.
Topics: Aged; Anticoagulants; Coronary Disease; Dalteparin; Exercise Test; Female; Follow-Up Studies; Humans | 2000 |
Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography | 2000 |
Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography | 2000 |
Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography | 2000 |
Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography | 2000 |
Concerning to low molecular weight heparins (LMWHs) in acut coronary syndromes.
Topics: Coronary Disease; Dalteparin; Double-Blind Method; Female; Fibrinolytic Agents; Humans; Male | 2000 |
The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy.
Topics: Aged; Biomarkers; Cohort Studies; Confidence Intervals; Coronary Disease; Dalteparin; Electrocardiog | 2002 |
Continuous multilead ST-monitoring identifies patients with unstable coronary artery disease who benefit from extended antithrombotic treatment.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Coronary Disease; Dalteparin; Dose-Response Relati | 2002 |
Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal coronary angioplasty.
Topics: Adult; Aged; Angiography; Angioplasty, Balloon, Coronary; Antibodies; Coronary Disease; Double-Blind | 1999 |
57 other studies available for dalteparin and Coronary Disease
| Article | Year |
|---|---|
Intracoronary drug delivery: mechanically too rough, pharmacologically too weak?
Topics: Coronary Disease; Coronary Vessels; Fibrinolytic Agents; Humans; Injections, Intralesional; Nadropar | 2000 |
[Risk stratification in acute coronary syndrome].
Topics: Abciximab; Acute Disease; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Biomarkers; Clin | 2001 |
Bleeding events in patients receiving enoxaparin for the management of non-ST-elevation acute coronary syndrome (NSTEACS) at Dunedin Public Hospital, New Zealand.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Case-Control Studies; Clinical Trials as Topic; Coro | 2008 |
Evidence-based risk stratification to target therapies in acute coronary syndromes.
Topics: Acute Disease; Angina Pectoris; Anticoagulants; Biomarkers; Cardiac Catheterization; Clopidogrel; Co | 2002 |
Enoxaparin in unstable coronary artery disease.
Topics: Anticoagulants; Coronary Disease; Enoxaparin; Humans | 2002 |
Preoperative use of enoxaparin compared with unfractionated heparin increases the incidence of re-exploration for postoperative bleeding after open-heart surgery in patients who present with an acute coronary syndrome: clinical investigation and reports.
Topics: Acute Disease; Aged; Angina, Unstable; Blood Component Transfusion; Coronary Artery Bypass; Coronary | 2002 |
Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in the secondary prevention of acute coronary syndrome.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Artery Bypass; Coronary Dise | 2002 |
Enoxaparin and unfractionated heparin in acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Coronary Disease; Electrocardiography; Enoxaparin; Heparin; Humans; Thrombolytic Ther | 2002 |
Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacemen | 2003 |
Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in patients with acute coronary syndrome in Poland: modelling study from the hospital perspective.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Coronary Disease; Cost-Benefit Analysis; Dru | 2003 |
Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
Topics: Aged; Anticoagulants; Coronary Disease; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Ki | 2003 |
Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients.
Topics: Anticoagulants; Antithrombin III; Catheters, Indwelling; Cohort Studies; Coronary Disease; Dose-Resp | 2003 |
Enoxaparin in percutaneous interventions: when to monitor? A case series.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Blood Coagulation Tests; Coronary Disea | 2003 |
[Non-ST elevation acute coronary syndrome: changes of parameters of hemostasis during and after treatment with unfractionated heparin and enoxaparin].
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Coronary Disease; Enoxaparin; Female; Fibrinolytic Ag | 2003 |
Retroperitoneal hematoma following tirofiban and enoxaparin coadministration in a patient with acute coronary syndrome.
Topics: Acute Disease; Aged; Anticoagulants; Coronary Disease; Enoxaparin; Hematoma; Humans; Male; Partial T | 2003 |
Role of enoxaparin in the invasive management of the ACS patient.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Disease; Drug Therapy, Combi | 2004 |
Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Coronary Disease; E | 2004 |
Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Coronary Disease; Drug Administration | 2004 |
Enoxaparin in non-ST segment elevation acute coronary syndromes: duration of therapy is essential to benefit.
Topics: Acute Disease; Anticoagulants; Coronary Disease; Enoxaparin; Heparin; Humans; Syndrome | 2004 |
Enoxaparin versus heparin: the SYNERGY trial from an emergency medicine perspective.
Topics: Acute Disease; Anticoagulants; Coronary Disease; Emergency Medicine; Enoxaparin; Heparin; Humans; Ra | 2005 |
The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibito
Topics: Anticoagulants; Coronary Disease; Drug Interactions; Endothelium, Vascular; Enoxaparin; Fibrinolytic | 2005 |
A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
Topics: Aged; Anticoagulants; Coronary Disease; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Middl | 2005 |
[Is there a difference between low-molecular-weight heparins?].
Topics: Anticoagulants; Coronary Disease; Dalteparin; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Heparin | 2005 |
Clinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST elevations in clinical practice.
Topics: Aged; Anticoagulants; Coronary Disease; Enoxaparin; Female; Fibrinolytic Agents; Humans; Male; Myoca | 2006 |
[The best of thrombosis in 2006].
Topics: Anticoagulants; Cardiology; Clinical Trials as Topic; Coronary Disease; Enoxaparin; Humans; Myocardi | 2007 |
Macroscopic thrombus formation on angioplasty equipment following antithrombin therapy with enoxaparin.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Enoxaparin; Equipment | 2007 |
Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes.
Topics: Aged; Coronary Disease; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Ho | 2007 |
Guidelines for the management of acute coronary syndromes 2006.
Topics: Aged; Australia; Coronary Disease; Enoxaparin; Humans; Practice Guidelines as Topic; Syndrome | 2007 |
Catheter induced clot formation during angioplasty: an enoxaparin side effect?
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Enoxaparin; Equipment Failur | 2007 |
Fondaparinux in patients with impaired renal function: the right choice?
Topics: Anticoagulants; Coronary Disease; Enoxaparin; Fondaparinux; Humans; Kidney; Polysaccharides | 2008 |
Heparin-induced thrombocytopenia and paradoxical venous thromboses.
Topics: Aged; Axillary Vein; Coronary Disease; Diabetes Mellitus, Type 2; Enoxaparin; Female; Femoral Vein; | 1993 |
Cardiopulmonary bypass for heparin-induced thrombocytopenia: management with a heparin-bonded circuit and enoxaparin.
Topics: Aged; Anticoagulants; Cardiopulmonary Bypass; Coronary Disease; Enoxaparin; Heparin; Humans; Male; T | 1996 |
XIX congress of the European Society of Cardiology August 24-28, 1997, Stockholm, Sweden.
Topics: Amiodarone; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Anticoagulants; Arteriosclerosis | 1997 |
Impact of new pharmacologic agents in the treatment of acute thrombotic syndromes.
Topics: Abciximab; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; | 1999 |
Pursuing progress in acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Clinical Trials as Topic; Coronary Disease; Enoxapa | 1999 |
The end of the heparin pump? Low molecular weight heparins have practical advantages, but clinical advantages are small.
Topics: Anticoagulants; Coronary Disease; Cost-Benefit Analysis; Enoxaparin; Heparin, Low-Molecular-Weight; | 1999 |
LMW heparins: from transition to fruition.
Topics: Anticoagulants; Coronary Disease; Cost-Benefit Analysis; Enoxaparin; Heparin, Low-Molecular-Weight; | 1999 |
[The treatment of acute coronary syndromes of the "non-ST elevation" type with enoxaparin: the TIMI 11B study. Thrombolysis in Myocardial Infarct].
Topics: Acute Disease; Coronary Disease; Double-Blind Method; Electrocardiography; Enoxaparin; Fibrinolytic | 2000 |
Comparing the antithrombotic efficacy of a humanized anti-factor IX(a) monoclonal antibody (SB 249417) to the low molecular weight heparin enoxaparin in a rat model of arterial thrombosis.
Topics: Animals; Antibodies, Monoclonal; Blood Coagulation Tests; Blood Flow Velocity; Carotid Artery Thromb | 2000 |
Concomitant use of eptifibatide and enoxaparin in the medical management of a patient with a non-ST segment elevation acute coronary syndrome and in-stent restenosis.
Topics: Adult; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Drug Therapy, Combina | 2000 |
Enoxaparin and unfractionated heparin in acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Anticoagulants; Bias; Clinical Protocols; Coronary Disease; Electrocardiography; Enox | 2002 |
Superiority of enoxaparin over unfractionated heparin for the treatment of acute coronary syndromes.
Topics: Acute Disease; Anticoagulants; Coronary Disease; Enoxaparin; Heparin; Humans; Syndrome | 2002 |
Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes.
Topics: Coronary Disease; Enoxaparin; Fibrinolytic Agents; Humans; Thromboembolism; Venous Thrombosis | 2002 |
Guidelines for acute coronary syndrome without ST elevation.
Topics: Abciximab; Antibodies, Monoclonal; Coronary Disease; Electrocardiography; Enoxaparin; Humans; Immuno | 2002 |
Optimal strategy for administering enoxaparin to patients undergoing coronary angiography without angioplasty for acute coronary syndromes.
Topics: Acute Disease; Aged; Anticoagulants; Cardiac Catheterization; Coronary Angiography; Coronary Disease | 2002 |
Low molecular weight heparin in prevention of restenosis after PTCA.
Topics: Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Coronary Angiography; Coronary Disease; DNA | 1996 |
Local delivery of a low molecular weight heparin following stent implantation in the pig coronary artery.
Topics: Animals; Anticoagulants; Arteries; Catheterization; Coronary Disease; Coronary Vessels; Heparin, Low | 2000 |
The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Disease; Dalteparin; Dose-Response Re | 2003 |
The primacy of clinical effectiveness for cost effectiveness analysis.
Topics: Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Dalteparin; Fibrinolytic Agents; | 2003 |
An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease.
Topics: Abciximab; Adult; Aged; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Aspirin; C-Reactiv | 2005 |
Low-molecular-weight heparin during instability in coronary artery disease.
Topics: Anticoagulants; Coronary Disease; Dalteparin; Humans; Platelet Activation; Platelet Aggregation | 1996 |
Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology.
Topics: Abciximab; Alanine; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibo | 1999 |
Management of unstable coronary-artery disease.
Topics: Anticoagulants; Coronary Disease; Dalteparin; Humans; Intracranial Hemorrhages | 2000 |
Management of unstable coronary-artery disease.
Topics: Anticoagulants; Coronary Disease; Dalteparin; Hemorrhage; Humans; Troponin T | 2000 |
Management of unstable coronary-artery disease.
Topics: Aged; Anticoagulants; Coronary Disease; Dalteparin; Heparin, Low-Molecular-Weight; Humans; Myocardia | 2000 |
Acute coronary care and beyond: the expanding role of low-molecular-weight heparin.
Topics: Anticoagulants; Coronary Disease; Dalteparin; Heparin, Low-Molecular-Weight; Humans | 2001 |
Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Antigens, CD; Atherectomy; Corona | 2001 |